gliclazide and Diabetic Glomerulosclerosis studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Research Excerpts

Excerpt	Relevance	Reference
"Gliclazide is a 'second generation' oral hypoglycaemic agent."	7.75	Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. ( Avery, GS; Brogden, RN; Heel, RC; Holmes, B; Speight, TM, 1984)
"Gliclazide is a 'second generation' oral hypoglycaemic agent."	3.75	Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. ( Avery, GS; Brogden, RN; Heel, RC; Holmes, B; Speight, TM, 1984)
"Therefore, we compared the renal hemodynamic effects of dapagliflozin with gliclazide in type 2 diabetes."	2.94	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. ( Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH, 2020)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."	2.73	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
"Gliclazide-treated had similar kidney index, but lower glucose levels, sCr, BUN, and MAU, compared with both saline and 4-PBA-treated diabetic rats or saline-treated TM rats."	1.48	Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy. ( Ren, X; Wang, X; Zhang, M; Zhang, YW, 2018)
"Gliclazide and HP were administered daily via gavage for 8 weeks."	1.46	Renoprotective effect of Hypericum perforatum against diabetic nephropathy in rats: Insights in the underlying mechanisms. ( Abd El Aleem, DI; Abd El Motteleb, DM, 2017)
"Since chronic kidney disease due to diabetic nephropathy (DN) is becoming an ever larger health burden worldwide, more effective therapies are desperately needed."	1.43	Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. ( Ahmed, LA; El-Latif, HA; Hassanein, NM; Mahfoz, AM; Shoka, AA, 2016)
"Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury."	1.37	Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011)
"Gliclazide treatment, but not glibenclamide, significantly reduced the oxidative products and NAD(P)H oxidase."	1.32	Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. ( Fujita, T; Goto, A; Onozato, ML; Tojo, A, 2004)

Research

Studies (16)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (12.50)	18.7374
1990's	1 (6.25)	18.2507
2000's	2 (12.50)	29.6817
2010's	8 (50.00)	24.3611
2020's	3 (18.75)	2.80

Authors	Studies
van Bommel, EJM	1
Muskiet, MHA	1
van Baar, MJB	1
Tonneijck, L	1
Smits, MM	1
Emanuel, AL	1
Bozovic, A	1
Danser, AHJ	1
Geurts, F	1
Hoorn, EJ	1
Touw, DJ	1
Larsen, EL	1
Poulsen, HE	1
Kramer, MHH	1
Nieuwdorp, M	1
Joles, JA	1
van Raalte, DH	1
Sekar, V	1
Mani, S	1
Malarvizhi, R	1
Barathidasan, R	1
Vasanthi, HR	1
Saberi, M	1
Ramazani, Z	1
Rashidi, H	1
Saberi, A	1
Zhang, YW	1
Wang, X	1
Ren, X	1
Zhang, M	1
Safar, MM	1
Abdelsalam, RM	1
Ezel, T	1
Kocyigit, Y	1
Deveci, E	1
Atamer, Y	1
Sermet, A	1
Uysal, E	1
Aktaş, A	1
Yavuz, D	1
Oei, E	1
Samad, N	1
Visser, A	1
Chowdhury, TA	1
Fan, SL	1
Mahfoz, AM	1
El-Latif, HA	1
Ahmed, LA	1
Hassanein, NM	1
Shoka, AA	1
Abd El Motteleb, DM	1
Abd El Aleem, DI	1
Patel, A	1
MacMahon, S	1
Chalmers, J	1
Neal, B	1
Billot, L	1
Woodward, M	1
Marre, M	1
Cooper, M	1
Glasziou, P	1
Grobbee, D	1
Hamet, P	1
Harrap, S	1
Heller, S	1
Liu, L	1
Mancia, G	1
Mogensen, CE	1
Pan, C	1
Poulter, N	1
Rodgers, A	1
Williams, B	1
Bompoint, S	1
de Galan, BE	1
Joshi, R	1
Travert, F	1
Louro, TM	1
Matafome, PN	1
Nunes, EC	1
da Cunha, FX	1
Seiça, RM	1
Shestakova, MV	1
Onozato, ML	1
Tojo, A	1
Goto, A	1
Fujita, T	1
Holmes, B	1
Heel, RC	1
Brogden, RN	1
Speight, TM	1
Avery, GS	1
Wheeley, MS	1
Yu, JY	1
Xiong, NN	1
Guo, HF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]		200 participants (Anticipated)	Observational	2012-01-31	Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]		160 participants (Actual)	Interventional	2013-12-31	Active, not recruiting
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]	Phase 3	11,140 participants (Actual)	Interventional	2001-06-30	Completed
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]	Phase 4	135 participants (Actual)	Interventional	2016-10-31	Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]	Phase 3	104 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]		465 participants (Actual)	Interventional	2015-08-31	Completed
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]		8,494 participants (Actual)	Observational	2010-01-31	Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]		150 participants (Anticipated)	Interventional	2016-11-30	Active, not recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]	Phase 2	20 participants (Actual)	Interventional	2014-04-30	Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]		0 participants (Actual)	Interventional	2011-09-30	Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	kg (Mean)
Insulin Glargine, Metformin, Exenatide	-4.8
Insulin Glargine, Metformin, Prandial Insulin	0.7

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	µg/ml (Median)
Sitagliptin	0
Gliclazide	8.4

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmol/L (Median)
Sitagliptin	-0.2
Gliclazide	-0.1

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmHg (Median)
Sitagliptin	4
Gliclazide	-9

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	mmol/L (Median)
Sitagliptin	0.1
Gliclazide	-0.1

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	score on a scale (Median)
Sitagliptin	3
Gliclazide	1.8

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	score on a scale (Median)
Sitagliptin	9.5
Gliclazide	9.4

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Intervention	kg (Median)
Sitagliptin	-0.5
Gliclazide	-0.6

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

Intervention	dCt (Median)
Gliclazide	-1.12
Sitagliptin	0

Intervention	dCt (Median)
Sitagliptin	3.41
Gliclazide	2.09

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

Intervention	pg/ml (Median)
Sitagliptin	-0.07
Gliclazide	0.43

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	Participants (Count of Participants)
Sitagliptin	6
Gliclazide	10

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

Intervention	score on a scale (Median)
	DLQI	HAQ-8	HADS Anxiety	HADS Depression	EQ-5D
Gliclazide	-1.0	0.0	0	0	-0.2
Sitagliptin	0.0	0.0	-1	0	0

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

Article	Year
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney international, 2020, Volume: 97, Issue:1 Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method;	2020
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs, 1984, Volume: 27, Issue:4 Topics: Absorption; Animals; Blood Glucose; Blood Platelets; Clinical Trials as Topic; Diabetes Mellitus; Di	1984
[Clinical observation on diabetic nephropathy treated with alcohol of Abelmoschus manihot]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1995, Volume: 15, Issue:5 Topics: Acetylglucosaminidase; Aged; Albuminuria; beta 2-Microglobulin; Captopril; Diabetic Nephropathies; D	1995

Article	Year
Positive interaction of mangiferin with selected oral hypoglycemic drugs: a therapeutic strategy to alleviate diabetic nephropathy in experimental rats. Molecular biology reports, 2020, Volume: 47, Issue:6 Topics: Animals; Antioxidants; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephropathies; D	2020
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy. Vascular health and risk management, 2020, Volume: 16 Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie	2020
Involvement of glucose-regulated protein 78 and spliced X-box binding protein 1 in the protective effect of gliclazide in diabetic nephropathy. Diabetes research and clinical practice, 2018, Volume: 146 Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Gliclazide	2018
H2S donors attenuate diabetic nephropathy in rats: Modulation of oxidant status and polyol pathway. Pharmacological reports : PR, 2015, Volume: 67, Issue:1 Topics: Aldehyde Reductase; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies;	2015
Biochemical and Histopathological Investigation of Resveratrol, Gliclazide, and Losartan Protective Effects on Renal Damage in a Diabetic Rat Model. Analytical and quantitative cytopathology and histopathology, 2015, Volume: 37, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Diabetes Mellitus, Experimental; Dia	2015
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia. Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:9 Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2;	2016
Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats. Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:12 Topics: Amides; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; B	2016
Renoprotective effect of Hypericum perforatum against diabetic nephropathy in rats: Insights in the underlying mechanisms. Clinical and experimental pharmacology & physiology, 2017, Volume: 44, Issue:4 Topics: Animals; Antioxidants; Apoptosis; Body Weight; Collagen Type IV; Cyclooxygenase 2; Cytoprotection; D	2017
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. European journal of pharmacology, 2011, Feb-25, Volume: 653, Issue:1-3 Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia	2011
[Diabetes mellitus and chronic kideny disease: modern diagnostics and treatment]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2012, Issue:1 Topics: Albuminuria; Blood Glucose; Diabetic Nephropathies; Early Medical Intervention; Gliclazide; Glomerul	2012
Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney international, 2004, Volume: 65, Issue:3 Topics: Animals; Blood Pressure; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Diabetic Nephropathi	2004
ABC of diabetes: treatment. British medical journal (Clinical research ed.), 1982, Oct-30, Volume: 285, Issue:6350 Topics: Diabetes Mellitus; Diabetic Nephropathies; Gliclazide; Humans; Sulfonylurea Compounds	1982

gliclazide and Diabetic Glomerulosclerosis